The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Merck's revenues will wane -8.7% and EPS will drop -21.0%.
The average estimate for revenue is $11.24 billion. On the bottom line, the average EPS estimate is $0.83.
Last quarter, Merck reported revenue of $10.67 billion. GAAP reported sales were 9.0% lower than the prior-year quarter's $11.73 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.85. GAAP EPS of $0.52 for Q1 were 7.1% lower than the prior-year quarter's $0.56 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 63.3%, 230 basis points worse than the prior-year quarter. Operating margin was 18.2%, 650 basis points worse than the prior-year quarter. Net margin was 14.9%, 10 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $45.18 billion. The average EPS estimate is $3.49.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 2,710 members out of 2,928 rating the stock outperform, and 218 members rating it underperform. Among 767 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 729 give Merck a green thumbs-up, and 38 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Merck is outperform, with an average price target of $48.14.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Merck. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Merck to My Watchlist.